Program
Tetrodotoxin
Also written as “Halneuron”.
Its studies are mostly in Pain · Neuralgia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wex Pharmaceuticals | 60 open or running | phase 3since Jul 28, 2008 | Jul 28, 2008 | none ahead |
| Dogwood Therapeutics | 11 open or running | phase 2since Feb 3, 2025 | Feb 3, 2025 | Dec 2026phase 2 · NCT06848348 |
Also a collaborator on its studies: celerion and premier-research-group-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2008First studies: 2 phase 3 studies in PainNew to Wex PharmaceuticalsWex Pharmaceuticals · NCT00726011, NCT00725114
- Jan 23, 2012Phase 1 study in HealthyWex Pharmaceuticals · NCT01527734 · 44 enrolled · United States
- Jul 19, 2012Phase 2 study in PainWex Pharmaceuticals · NCT01655823 · 125 enrolled · United States
- Sep 6, 2019Phase 1 study in TQT StudyWex Pharmaceuticals · NCT04083833 · 25 enrolled · United States
- Apr 25, 2022Phase 2 study in PainWex Pharmaceuticals · NCT05359133 · 35 enrolled · United States
- Feb 3, 2025Dogwood Therapeutics's first study: phase 2 study in PainNew to Dogwood TherapeuticsDogwood Therapeutics · NCT06848348 · 240 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 2 study in PainDogwood Therapeutics · NCT06848348
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06848348Pain · United States | 2 | Active, not recruiting | Dogwood Therapeutics | Dec 2026 | 240 |
| NCT05359133Pain · United States | 2 | Terminated | Wex Pharmaceuticals | Oct 14, 2024 | 35 |
| NCT04083833TQT Study · United States | 1 | Completed | Wex Pharmaceuticals | Mar 24, 2018 | 25 |
| NCT01655823Pain · United States | 2 | Terminated | Wex Pharmaceuticals | Jan 2015 | 125 |
| NCT01527734Healthy · United States | 1 | Completed | Wex Pharmaceuticals | Jan 2012 | 44 |
| NCT00726011Pain · Canada | 3 | Completed | Wex Pharmaceuticals | Dec 2011 | 113 |
| NCT00725114Pain · Canada | 3 | Completed | Wex Pharmaceuticals | Nov 2012 | 165 |
How it is read
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.